FDA Investigator Kathryn E King
Kathryn E King has conducted inspections on 2 sites in 1 countries as of 27 Oct 2020. See below for a list of the FDA enforcement documents resulting from those inspections.
Investigator Details
Number of Inspected Sites:
2
Last Inspection Date:
27 Oct 2020
Investigator Role:
FDA Investigator
Redica ID:
Countries of Inspections:
United States of America
FDA Investigators that have inspected at least one site in common with Kathryn E King:
Amir Alavi,
Andrew "Drew" Haack, PhD,
Andrew K Haack, PhD,
Anita Narula, PhD,
Arie C Menachem,
Ashar P Parikh,
Barbara Janine Breithaupt,
Bo Chi, PhD,
Brian M Janelsins, PhD,
Carl Lee,
Carolyn A Renshaw,
CDR Donald Ertel,
CDR Ileana Barreto Pettit,
CDR Rochelle B Young, RPh, MSA,
Charles Yuanchia Kuo, PhD,
Chava Kimchi Sarfaty, PhD,
Christopher R Czajka,
Colleen F Hoyt,
David G Eng,
Deborah M Trout,
Henry K Lau,
James R Evans,
Jeffrey M Watson,
Joan Johnson,
Joseph Kutze, PhD,
Keith O Webber, PhD,
Keith Webber, PhD,
Kouros Kangarli,
Lance Mde Souza, MBA,
Laurie Graham,
Linan Ha, PhD,
Lisa K Capron,
Lucila B Nwatu,
Mariza M Jafary,
Marshalette O Edwards,
Michael S Araneta,
Michelle Rfrazier Jessen, PhD,
Mihaly S Ligmond,
Mikhail V Ovanesov, PhD,
Milos Dokmanovic, PhD,
Natalia Pripuzova, PhD,
Nataniel Phillips Sylvain, PhD,
Nicholas L Hunt,
Patricia F Hughes, PhD,
Peter E Baker,
Prabhu P Raju,
Qing Joanna Zhou, PhD,
Rabia Ballica, PhD,
Rebecca Rodriguez,
Reyes Candau Chacon, PhD,
Richard Ledwidge (nmi), PhD,
Riley C Myers, PhD,
Robert D Tollefsen,
Ruth Moore, PhD,
S Lori Brown, PhD MPH,
Scott N Lim,
Sharon K Thoma, PharmD,
Sidney B Priesmeyer,
Stephanie A Slater, MS,
Teegan Dellibovi Ragheb, PhD,
Thomas J Arista,
Thuy T Nguyen, LCDR,
Uttaniti Limchumroon (Tom),
V Teres Speer,
Vanessa Y Gelsey, PhD,
Vanessa Y Jacobs,
Wayne E Seifert,
William V Millar,
Yideng Liang,
Yuan Chia Kuo,
Zhong Li, PhD
Kathryn E King's Documents
| Publish Date | Document Type | Title |
|---|---|---|
| November, 2020 | FDA 483 Response | AGC Biologics, Inc. - Form 483R, 2020-11-23 |
| November, 2020 | EIR | AGC Biologics, Inc. - EIR, 2020-11-02 |
| November, 2020 | FDA 483 | AGC Biologics, Inc. - Form 483, 2020-11-02 |
| March, 2012 | FDA 483 | Genentech, Inc. - Form 483, 2012-03-28 |
| June, 2024 | FDA 483 | STgen Bio Co., Ltd. - Form 483, 2024-06-25 |
Experience Redica Systems’ NEW investigator profiles and dashboards
Redica Systems customers get access to over 1,400 FDA Investigator profiles, containing powerful analysis like:
- Total inspections conducted
- 483 rate
- OAI rate
- Warning Letter rate
- Inspections by Industry, Scope, and Inspection Reason
- And much more
Investigator Profiles are not sold as on-demand documents. If you’d like to see one, fill out the form below to connect with our Sales Team and get it in your inbox as little as 24 hours.
Talk to sales to access our investigator profiles
Loading...
Investigator Profiles Are Just the Tip of the Iceberg
Becoming a Redica Systems customer not only provides you with unlimited access to profiles similar to the one above for every current and former FDA Investigator, but also grants you access to:
Inspection Intelligence
- Pre-Approval Inspection (PAI) trends
- The ability to filter nearly any FDA enforcement action by GxP labels like GMP, GCP, etc.
- Latest 483s: see what the trends are across all FDA Investigators
- CFR Heatmap: Citations aggregated by Subpart by Year
Vendor Intelligence
- Full inspection histories for your vendors down to the specific site level
- All of the functionality mentioned above but isolated to just your vendors
Regulatory Intelligence
- Zero in on the trends for a specific agency/regulator (ex. FDA, MHRA, EMA, Health Canada)
- All the latest "Signals" from agencies around the world, segmented by Country, Type (ex. Guidance, Decree...), Category (ex. Rules/Regulations/Guidance, News, Reports...), Theme (ex. Cell and Gene Therapy, AI...), and more